Ratings Valneva SE Pref. Euronext Paris

Equities

VLAP

FR0011472943

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-7.89%	-28.57%

07/05	Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
07/05	Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
VALNEVA SE PREF.	-28.57%	503M	-
MODERNA, INC.	+17.96%	44.96B	B-
IQVIA HOLDINGS INC.	+1.17%	42.65B	B
LONZA GROUP AG	+48.77%	41.85B	A
CELLTRION, INC.	-4.27%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B	B
BIO-TECHNE CORPORATION	+4.86%	12.75B	B+
MEDPACE HOLDINGS, INC.	+27.29%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes